Biophan CEO Michael Weiner Featured on World Talk Radio's ``Science and Society'' Program, Available Online; Co-Founder and CEO Discusses Company's Next-Generation Biomedical Solutions for Improved Medical Devices and MRI.

ROCHESTER, N.Y. -- Biophan Technologies, Inc. (OTCBB: BIPH), a developer of next-generation medical technology, announced today the online availability of an audio interview given by CEO Michael Weiner to radio talk show "Science and Society," a program of World Talk Radio. The 15-minute discussion with host Dr. David Lemberg focuses on Biophan's groundbreaking scientific advances in several multi-billion-dollar biomedical markets.

In the interview, Mr. Weiner discusses the growing need for solutions that will enable improved safety and compatibility of Magnetic Resonance Imaging (MRI) systems for patients that have implanted medical devices. Biophan develops enabling technologies for implantable medical devices, such as pacemakers and stents, and interventional surgical devices, such as catheters, guidewires, and other products. Mr. Weiner outlines Biophan's multi-pronged, strategic business and technology approaches to making these devices both safe and/or fully compatible with MRI.

MRI systems are uniquely powerful diagnostic imaging devices, but a growing body of medical evidence suggests that they are contraindicated for use with certain common implanted medical devices, such as pacemakers, defibrillators, and neurostimulators, because of risks that the devices may heat up in the body to dangerous levels or be affected by induced electrical voltages. The FDA has recently issued updated medical advisories about these risks.

Additionally, devices such as stents can be enabled by Biophan technology to be imaged for restenosis without the need for an invasive procedure.

Mr. Weiner pointed out that for many of these problems, Biophan already has proven solutions. "Three million people worldwide with implanted pacemakers cannot undergo an MRI procedure without a fairly serious risk of harm," Mr. Weiner said in the interview. But that will change in the foreseeable future, as device manufactures seek to catch up with the technology solutions now available. Biophan is executing a business strategy to leverage its proprietary technology and solutions to create improved products in a number of multi-billion-dollar biomedical markets, including drug-delivery and drug-elution, as well as (MRI) safety and compatibility for medical devices.

To listen to the online interview, please visit http://www.worldtalkradio.com/archive.asp?aid=4247.

About Biophan Technologies

Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and compatible with the magnetic resonance imaging (MRI) environment. The Company develops enabling technologies for implanted medical systems such as pacemakers and interventional surgical devices such as catheters, guidewires, stents, and other implants to allow them to be safely and effectively imaged under MRI. The technology is also being used to create MRI contrast agents, and has expanded to include other applications, such as drug delivery and power systems derived from body heat. Four Biophan technologies include advances in nanotechnology and thin film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors now hold a total of 127 U.S. patents, licenses, or applications. This total includes 37 issued U.S. patents, 8 recently-allowed applications that will issue as patents in the near future, and 82 pending applications at various stages of examination at the U.S. Patent and Trademark Office, plus international applications. The patents cover areas including nanotechnology (nanomagnetic particle coatings), radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat, and photonics. Biophan has joint development arrangements with Boston Scientific (NYSE: BSX) and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. For more information, please visit www.biophan.com.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements included in this press release may constitute forward-looking statements within the meaning of applicable securities laws. These statements reflect what Biophan anticipates, expects, or believes may happen in the future. Biophan's actual results could differ materially from the outcome or circumstance expressed or implied by such forward-looking statements as a result of a variety of factors including, but not limited to: Biophan's ability to develop its technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the ability of Biophan to demonstrate the effectiveness of its technology; the acceptance by the market of Biophan's technology and products incorporating such technology, the ability of Biophan to effectively negotiate and enter into contracts with medical device manufacturers for the licensing of Biophan's technology; competition; the ability of Biophan to raise capital to fund its operating and research and development activities until it generates revenues sufficient to do so; and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC which are incorporated herein by reference. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.